Nyheter om peptidindustrin
Kommersiella rörelser, regleringsåtgärder och marknadsförändringar inom peptid- och GLP-1-området - uppdateras dagligen.
Ambrosia Biosciences Raises $100M to Develop Small-Molecule GLP-1 Pills That Could Replace Injections
Colorado-based Ambrosia Biosciences closed an oversubscribed $100M Series B to advance oral small-molecule GLP-1 therapies for obesity, aiming to move beyond peptide-based injections like Ozempic and Mounjaro with a Phase 1 trial of its lead candidate.
Source: Unknown
Senaste uppdateringarna
APhA 2026: Pharmacists Say GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease
At the 2026 American Pharmacists Association Annual Meeting in Los Angeles, experts presented evidence that GLP-1 receptor agonists have expanded far beyond diabetes into cardiovascular, liver, and kidney disease — challenging pharmacists to keep pace.
via Unknown
Daiichi Sankyo Partners With Meddenovo to Use AI for Designing Cyclic Peptide Drug Candidates
Japanese pharma giant Daiichi Sankyo has partnered with AI drug design company Meddenovo to accelerate the discovery of cyclic peptide-based therapeutics using AI and physical computational approaches, signaling growing industry interest in the peptide modality beyond GLP-1.
via Unknown
Neuland Laboratories to Open $30M Commercial Peptide Manufacturing Facility in India
India-based CDMO Neuland Laboratories will open a commercial-scale peptide manufacturing facility at its Hyderabad campus in summer 2026, adding 6,370 liters of synthesis capacity to meet surging global demand driven by the GLP-1 boom.
via Unknown
Peptide Sciences Shuts Down After FDA Crackdown on Gray-Market Vendors
Peptide Sciences, the largest U.S. gray-market research peptide vendor with $7.45 million in December 2025 sales, voluntarily closed on March 6, 2026 amid escalating FDA and DOJ enforcement actions targeting unlicensed peptide suppliers.
via Unknown
ProPublica Investigation Warns FDA Peptide Reversal Could Open Market to Unsafe Drugs
A ProPublica investigation raises safety concerns about the FDA's expected reclassification of 14 restricted peptides, arguing that compounding pharmacies lack the quality controls needed to ensure patient safety for complex peptide formulations.
via Unknown
Structure Therapeutics Reports 16.3% Weight Loss With Oral GLP-1 Pill Aleniglipron in Phase 2 Trial
Structure Therapeutics' once-daily oral GLP-1 receptor agonist aleniglipron achieved 16.3% placebo-adjusted weight loss at 44 weeks in the Phase 2 ACCESS II trial, with no plateau in the weight-loss curve — setting up a Phase 3 program in late 2026.
via Unknown
At Least 14 US States Have Built Their Own Peptide Rules Beyond FDA — Creating a Regulatory Patchwork
While the FDA moves to reclassify 14 peptides from Category 2 back to Category 1, at least 14 US states have enacted additional restrictions that exceed federal requirements, creating conflicting standards for compounding pharmacies, clinicians, and patients across state lines.
via Unknown
Eli Lilly's Tirzepatide Achieves First Pediatric Type 2 Diabetes Approval
FDA grants tirzepatide approval for patients ages 10-17 with type 2 diabetes, marking the first GLP-1/GIP dual agonist authorized for pediatric use and opening treatment options for a growing childhood obesity crisis.
via Unknown
FDA Launches Novel Peptide Safety Initiative Following RFK Jr. Directive
The agency announces comprehensive review of peptide supplement market and new enforcement framework, aiming to distinguish between legitimate therapeutics and unapproved compounds marketed as supplements.
via Unknown
New Peptide-Drug Conjugate Technology Shows Promise for Targeted Cancer Treatment
Researchers at MIT develop novel peptide-drug conjugate platform enabling precise tumor targeting while sparing healthy tissue, potentially reducing side effects of traditional chemotherapy.
via Unknown
Novo Nordisk Announces $12B Manufacturing Expansion to Meet GLP-1 Demand
The Danish pharmaceutical giant commits largest-ever capital investment to double peptide production capacity by 2028, responding to unprecedented global demand for Ozempic and Wegovy.
via Unknown
Why the New GLP-1 Pill Is Such a Big Deal for Peptide Therapeutics
The shift from injectable to oral GLP-1 receptor agonists marks a turning point for peptide drug delivery. Vox explores how a daily pill could reshape the $33 billion diabetes and obesity market.
via Unknown
GLP-1 Receptor Agonists Show Promise Reducing Liver Stiffness in Pediatric Metabolic Disease
A new study demonstrates that GLP-1 receptor agonists reduce liver stiffness in pediatric patients with metabolic dysfunction-associated steatotic liver disease, while normalizing disease-associated gene expression in experimental models.
via Unknown
Peptide Manufacturing Comes of Age as GLP-1 Boom Drives Production Scale-Up
The explosive demand for GLP-1 receptor agonists is pushing peptide manufacturing capabilities to new heights, with contract manufacturers investing billions to meet production needs for semaglutide, tirzepatide, and next-generation peptide drugs.
via Unknown
Social Media Influencers Promote Peptides for Health and Anti-Aging — But Where Is the Evidence?
A growing number of social media influencers are touting peptide injections for enhanced health and anti-aging, but scientists caution that clinical evidence for many promoted uses remains thin or nonexistent.
via Unknown
Avacta Treats First Patient in Phase 1 Trial of Sustained-Release Peptide Drug Conjugate AVA6103
Avacta Therapeutics has dosed the first patient in its FOCUS-01 Phase 1 trial of FAP-Exd (AVA6103), a sustained-release exatecan peptide drug conjugate targeting fibroblast activation protein in solid tumors.
via Unknown
FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes
The FDA is expected to ease restrictions on peptide therapies, a move championed by Health Secretary Robert F. Kennedy Jr. as part of a broader push to expand access to alternative treatments. The decision could reshape the regulatory landscape for compounded peptides in the United States.
via Unknown
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly - CNBC
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly - CNBC
via CNBC
The Wellness World Is Eager for RFK Jr.'s Promised Move on Peptides
NPR reports on the anticipation within the wellness community as RFK Jr. signals plans to lift FDA restrictions on certain peptide compounds, raising both excitement and concern among health professionals.
via Unknown
Natural Peptide in Sweat May Help Block Flu Infection Before Symptoms Start
Researchers have identified a naturally occurring antimicrobial peptide in human sweat that shows potential for blocking influenza infection at the earliest stages, before symptoms develop.
via Unknown
Weight Watchers says eligible members can save $1,200 a year on Wegovy - Stock Titan
Weight Watchers says eligible members can save $1,200 a year on Wegovy - Stock Titan
via Stock Titan
Can weight-loss drugs go needle-free? BioNxt tests thin-film version - Stock Titan
Can weight-loss drugs go needle-free? BioNxt tests thin-film version - Stock Titan
via Stock Titan
Peptides Move from Fringe Biohacks to Functional Food Frontier
FoodNavigator-USA reports on the emerging trend of incorporating bioactive peptides into functional foods, as the ingredient category transitions from niche biohacking circles to mainstream food and beverage products.
via Unknown
The Guardian View on Peptides: RFK Jr Would Leave Public Health Policy to the Hucksters
In a scathing editorial, The Guardian argues that Health Secretary RFK Jr.'s push to expand peptide access amounts to deregulating health products without adequate scientific backing, potentially endangering public health.
via Unknown
GLP-1 unicorn raises $200 million from Tom Brady, others - Axios
GLP-1 unicorn raises $200 million from Tom Brady, others - Axios
via Axios
Q&A: Should You Trust Trending Peptide Injections?
UVA researchers weigh in on the growing popularity of peptide injections, urging consumers to look beyond social media hype and evaluate the limited clinical evidence behind many trending compounds.
via Unknown
FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Take Down. What’s Next? - pharmacytimes.com
FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Take Down. What’s Next? - pharmacytimes.com
via pharmacytimes.com
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - HIMS Investor Relations
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - HIMS Investor Relations
via HIMS Investor Relations
OrbiMed-Backed Pinnacle Adds $89M Series B to Power Oral Peptide Pipeline
Pinnacle Biopharma secures a major $89 million Series B funding round led by OrbiMed, signaling strong investor confidence in the future of oral peptide drug delivery technologies.
via Unknown
Wegovy: FDA Approves Higher Dose Shot for Greater Weight Loss - Healthline
Wegovy: FDA Approves Higher Dose Shot for Greater Weight Loss - Healthline
via Healthline
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top - CNBC
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top - CNBC
via CNBC
Recently Approved Wegovy Pill Expands Access to GLP-1 Therapy for Chronic Weight Management - pharmacytimes.com
Recently Approved Wegovy Pill Expands Access to GLP-1 Therapy for Chronic Weight Management - pharmacytimes.com
via pharmacytimes.com
Can AI Tools Help Identify Next-Gen Peptide Therapeutics?
The American Medical Association explores how artificial intelligence and machine learning are accelerating the discovery of novel peptide-based drugs, potentially transforming the pharmaceutical pipeline.
via Unknown
Get Ready for the Peptides Gold Rush
Medical Marketing and Media reports on the surging commercial interest in peptide therapies, as pharmaceutical companies, compounding pharmacies, and wellness brands race to capture a rapidly growing market.
via Unknown
Want to Hack Your Body with Peptides? If Only the Science Agreed
The Economist takes a measured look at the booming peptide wellness trend, examining the gap between enthusiastic consumer adoption and the still-developing scientific evidence behind many popular peptide therapies.
via Unknown
FDA Update: EPIPEN E Z PEN
FDA submission update for VIATRIS.
via FDA